Clinical Trials Logo

Filter by:
NCT ID: NCT00616902 Terminated - Clinical trials for Hypertrophy, Left Ventricular

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

PRIMO II
Start date: January 2009
Phase: Phase 3
Study type: Interventional

To evaluate the effects of paricalcitol injection on cardiac structure and function over 48 weeks in subjects with Stage 5 Chronic Kidney Disease (CKD) receiving hemodialysis who have left ventricular hypertrophy (LVH).

NCT ID: NCT00616551 Completed - Acromegaly Clinical Trials

Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

Start date: April 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the biological safety and efficacy of using the drug, C2L-OCT-01 PR, 30 mg to treat acromegalic patients.

NCT ID: NCT00614939 Completed - Type 2 Diabetes Clinical Trials

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

Start date: January 2008
Phase: Phase 3
Study type: Interventional

Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.

NCT ID: NCT00614055 Completed - Clinical trials for Diabetes Mellitus, Type 2

Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Start date: January 2008
Phase: Phase 2
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes.

NCT ID: NCT00611455 Terminated - Clinical trials for Arthritis, Rheumatoid

Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy

Start date: January 1, 2008
Phase: Phase 3
Study type: Interventional

This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period. the primary purpose of the study is to demonstrate the efficacy of ofatumumab in reducing clinical signs and symptoms in adult RA patients after a single course of ofatumumab.

NCT ID: NCT00611026 Completed - Overactive Bladder Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Start date: February 2008
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

NCT ID: NCT00610714 Completed - Ovarian Cancer Clinical Trials

AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

OVERT-1
Start date: April 2008
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer

NCT ID: NCT00605891 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Dose Finding Study of CHF 4226 for Treating Patients With COPD

Start date: October 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to identify the optimal once-daily dose of CHF 4226 to be further developed for the treatment of patients with COPD.

NCT ID: NCT00605215 Completed - Multiple Sclerosis Clinical Trials

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

BRAVO
Start date: April 24, 2008
Phase: Phase 3
Study type: Interventional

The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing Multiple Sclerosis (MS) injectable drug: Interferon β-1a (Avonex®).

NCT ID: NCT00603239 Completed - Clinical trials for Type 2 Diabetes Mellitus

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

Start date: January 2008
Phase: Phase 3
Study type: Interventional

This study will assess safety and efficacy of exenatide in combination with a thiazolidinedione (TZD) and a TZD plus metformin over 26 weeks in adult patients with type 2 diabetes who have not achieved adequate glycemic control.